Cellular Immunotherapy for Prostate Cancer: Lessons Learned From 15 Years of Sipuleucel‐T
Neal D. Shore, Emmanuel S. Antonarakis, Jason Hafron, Kelvin A. Moses, Christopher Pieczonka, Benjamin Lowentritt, Nadeem Sheikh, Daniel J. George, Tanya Barauskas Dorff · 2025
Read Cellular Immunotherapy for Prostate Cancer: Lessons Learned From 15 Years of Sipuleucel‐T by Neal D. Shore, Emmanuel S. Antonarakis, Jason Hafron, Kelvin A. Moses, Christopher Pieczonka, Benjamin Lowentritt, Nadeem Sheikh, Daniel J. George, Tanya Barauskas Dorff (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12767674.txt.
Description
Neal Shore and eight co-authors take stock of fifteen years of the first cellular immunotherapy for prostate cancer, in this 2025 review. Sipuleucel-T is made from the patient's own immune cells, collected, trained in a lab to attack a protein found on prostate tumors, and returned to the body. It won approval in 2010 for advanced prostate cancer that no longer answers to hormone therapy.
Since then, trials and everyday practice have sharpened the picture of whom it helps. It lengthens survival in men whose disease is advanced but not yet demanding opioid pain relief. Longer survival clusters with lower disease burden at treatment, stronger immune responses after treatment, and differences by race that researchers are still unpacking. Newer drugs have crowded the field, yet none works the way this living therapy does. The review argues for using it earlier and in the right patients.
Catalog record
| CREATOR | Neal D. Shore, Emmanuel S. Antonarakis, Jason Hafron, Kelvin A. Moses, Christopher Pieczonka, Benjamin Lowentritt, Nadeem Sheikh, Daniel J. George, Tanya Barauskas Dorff |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 46 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |